Estrogen exposure, in the setting of pregnancy, the postpartum state, combined hormonal
contraceptives (CHCs), or hormone therapy use, has been clearly associated with increased …

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of
the potential for fetal complications. It is unknown whether the use of hormonal therapy …

Background Although heavy menstrual bleeding (HMB) is a known complication of
anticoagulant therapy, rates of HMB in users of the direct oral anticoagulants (OACs) …

Anticoagulants increase the risk of heavy menstrual bleeding (HMB). We sought to
investigate the incidence, predictors and management of HMB in women on rivaroxaban …

Abnormal or excessive menstrual bleeding affects one‐third of reproductive‐aged women.
This number increases to 70% among women on direct oral anticoagulants (DOACs). While …

Heavy menstrual bleeding (HMB) is a common complication of anticoagulation, affecting∼
70% of menstruating women receiving oral anticoagulants. The risk of HMB is lower with …

Background Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect
is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin …

Anticoagulation is sometimes needed during pregnancy and/or the postpartum period in
individuals at high risk of deep vein thrombosis, a history of venous thromboembolism, with …

Background: Venous thromboembolism (VTE) is a frequent and serious disease that
requires immediate and long-term anticoagulant treatment, which is inevitably associated …

Abnormal uterine bleeding (AUB) is a common complication of anticoagulant therapy in
premenopausal women affected with acute venous thromboembolism. AUB impacts quality …